Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Overview: Strong knowledge of data structures and recognizing common patterns makes complex coding questions easier and faster to solve.Thinking out loud during ...

IntroductionIn December 2025, Zscaler ThreatLabz discovered a campaign linked to APT37 (also known as ScarCruft, Ruby Sleet, and Velvet Chollima), which is a DPRK-backed threat group. In this campaign ...

Information concerning registration for the LRA 2026 conference, which will include a keynote address by Dr. Yolanda Sealey-Ruiz, is expected to be released shortly on the Literacy Research ...

The rapid advancement of Artificial Intelligence has moved us from simple chatbots to autonomous agents. These agents do not just answer questions; they plan, use tools, and execute tasks with minimal ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Charlene Rhinehart is a CPA , CFE, chair of an Illinois CPA Society committee, and has a ...

The new version of the container and VM manager extends GPU support for AMD hardware and introduces cluster recovery ...

Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...